BRIEF published on 11/25/2025 at 21:47, 4 months 1 day ago Suspension temporaire de la cotation des actions Transgene Euronext Paris Biotechnologie Augmentation De Capital Cotation Transgene
BRIEF published on 11/25/2025 at 21:47, 4 months 1 day ago Temporary suspension of trading in Transgene shares Euronext Paris Biotechnology Capital Increase Transgene Quoting
PRESS RELEASE published on 11/25/2025 at 21:42, 4 months 1 day ago Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris Transgene requests temporary suspension of trading on Euronext Paris pending capital increase results. Trading to resume on November 27, 2025 Euronext Paris Trading Capital Increase Suspension Transgene
PRESS RELEASE published on 11/25/2025 at 21:42, 4 months 1 day ago Correction: Transgene annonce la suspension temporaire de la cotation de ses actions sur Euronext Paris Transgene suspend temporairement la cotation de ses actions sur Euronext Paris en attendant les résultats de son augmentation de capital. Reprise prévue le 27 novembre 2025 Euronext Paris Augmentation De Capital Cotation Suspension Transgene
BRIEF published on 11/25/2025 at 20:46, 4 months 1 day ago Temporary Suspension of Trading in Transgene Shares on Euronext Paris Euronext Paris Biotechnology Capital Increase Transgene Trading Suspended
BRIEF published on 11/25/2025 at 20:46, 4 months 1 day ago Suspension Temporaire de la Cotation des Actions de Transgene sur Euronext Paris Euronext Paris Biotechnologie Augmentation De Capital Suspension De Cotation Transgene
PRESS RELEASE published on 11/25/2025 at 20:41, 4 months 1 day ago Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris Transgene requests temporary suspension of trading on Euronext Paris pending capital increase results Euronext Paris Trading Capital Increase Suspension Transgene
PRESS RELEASE published on 11/25/2025 at 20:41, 4 months 1 day ago Transgene annonce la suspension temporaire de la cotation de ses actions sur Euronext Paris Transgene demande la suspension temporaire de la cotation de ses actions sur Euronext Paris en attendant la publication du résultat de son augmentation de capital Euronext Paris Augmentation De Capital Cotation Suspension Transgene
BRIEF published on 11/25/2025 at 19:20, 4 months 1 day ago Transgene Launches €105 Million Fundraising Initiative Biotechnology Investment Transgene Fundraising Myvac® Program Cancer Vaccine Development Institutional And Retail Offerings
BRIEF published on 11/25/2025 at 19:20, 4 months 1 day ago Transgene lance une initiative de levée de fonds de 105 millions d'euros Investissement En Biotechnologie Collecte De Fonds Pour Les Transgènes Programme Myvac® Développement De Vaccins Contre Le Cancer Offres Institutionnelles Et De Détail
Published on 03/26/2026 at 23:00, 2 hours 51 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 3 hours 46 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 3 hours 51 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 3 hours 51 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 4 hours 51 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 20:48, 5 hours 3 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 6 hours 31 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 6 hours 41 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 6 hours 41 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 7 hours 34 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 7 hours 34 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 7 hours 51 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 7 hours 51 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité
